Phase II study of PS-341 [bortezomib] in patients with metastatic malignant melanoma
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2013
At a glance
- Drugs Bortezomib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
- 25 Oct 2007 Status changed from in progress to completed.
- 24 Sep 2005 New trial record.